Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

Condensed Consolidated Balance Sheets

(In thousands, except par value)

December 31, December 31,

2007 2006

Assets

Current assets:

Cash and cash equivalents $27,066 $24,301

Accounts receivable 4,689 2,319

Prepaid expenses and other current assets 2,579 2,048

Total current assets 34,334 28,668

Property and equipment, net 4,390 3,357

Goodwill 6,462 6,917

Patents, net 7,680 8,850

Other assets 196 321

Restricted cash 3,190 3,059

Total assets $56,252 $51,172

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable $2,335 $1,680

Accrued expenses 4,765 10,153

Warrant liabilities 5,218 -

Other liabilities 520 366

Short-term note - 1,320

Current portion of long-term debt obligations 2,401 599

Current portion of deferred revenue 3,360 2,972

Total current liabilities 18,599 17,090

Deferred revenue, net of current portion 8,366 195

Other non-current liabilities 2,055 1,961

Long-term debt obligations, net of current

portion
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Grace Century, a private equity consultancy ... the addition of Dr. Yousef “Josh” Siddiqui , ... Dr. Siddiqui will provide further healthcare expertise to its ... University College Medical School in the late ... 2001. With further certification as a General Practitioner (GP), ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ... today announced next steps for its Oral Amphotericin ... from its in vitro work involving ... iCo now plans to complete pre clinical studies ... initial Phase 1A clinical trial, utilizing approximately $700,000 ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market ... Labeling Systems, Table-top Counters) by End-user (Inpatient Pharmacy ... Trends to 2019” analyzes and studies the major ... Europe, Asia-Pacific, and the Rest of the World ... figures spread through 300 pages and in-depth TOC ...
(Date:10/20/2014)... Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or ... brings Q3 orders to $5.8 million and provides a good start ... North America and one in the ... new projects at record levels," said Peter Bruijns , President ... the end of Q3 than they have been for any complete ...
Breaking Biology Technology:Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... January 12 Bavarian Nordic,owns several United States ... core technology, MVA-BN(R), which is the basis for ... a vector for delivering,recombinant vaccines. Bavarian Nordic has ... infringement action. The claim in this case is ...
... ALAMEDA, Calif., Jan. 12 Singulex, Inc. today announced ... led by JAFCO Co., Ltd. and supported by existing ... round will support the commercialization of Singulex technologies in ... Hozoji, investment officer for JAFCO Life Science Investment, will ...
... Pharmaceuticals today,announced that it has achieved its first candidate ... GlaxoSmithKline. Anacor may,receive future milestone payments and royalties ... sales. , "We are pleased ... result of,the alliance we have built between our team ...
Cached Biology Technology:Bavarian Nordic's Case Against Oxford BioMedica 2Singulex Closes $19 Million Financing Round 2Anacor Achieves Milestone from GSK for Boron-Based Systemic Antibacterial Product Candidate 2
(Date:10/18/2014)... referred for evaluation of suspected genetic conditions, whole-exome ... percent, including detection of a number of rare ... according to a study appearing in JAMA ... with the American Society of Human Genetics annual ... coding regions of thousands of genes simultaneously using ...
(Date:10/17/2014)... Ebola is critical and pertinent for practicing physicians and ... and epidemic. The Journal, Disaster Medicine and Public ... Virus and Public Health, to surround the public, medical ... societal moment. , On October 17, the journal ... The primer was prepared by Dr. Eric Toner, internist ...
(Date:10/17/2014)... Copenhagen have shown for the first time how bacteria ... patients, giving them the opportunity to get tremendous insights ... The study also discovered the bacterial growth in chronic ... or slowed down by the immune cells. The researchers ... helped "suffocate" the bacteria, forcing the bacteria to switch ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
... , April 17, 2013 Vermillion, Inc. (NASDAQ: ... on gynecologic cancers and women,s health, announced the signing of ... U.S. Army Medical Research and Materiel Command (USAMRMC). ... Reduction Using OVA1 in a Treatment Algorithm for Adnexal ...
... 100% biodiesel (B100) "blend stock" samples by the U.S. ... that 95% of the samples from 2011-12 met ASTM ... guidelines for industry and are designed to ensure quality ... operation of the nation,s vehicles powered by biodiesel blends. ...
... 16, 2013 - BGI Health and ACIBADEM Healthcare ... Company Molecular Biology, signed a Memorandum of Understanding ... technologies to Turkey and improving Turkish reproductive healthcare. ... testing technologies in the areas of Monogenic disorders, ...
Cached Biology News:U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 2U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 3U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care 4NREL survey shows dramatic improvement in B100 biodiesel quality 2BGI Health forms partnership with ACIBADEM hospital on genetic disease testing 2